Valo Therapeutics (ValoTx) is a developer of novel immunotherapies in cancer and infectious disease. Our unique approach to immunotherapy, based on oncolytic viruses and viral vectors combined with disease-specific peptides, delivers highly adaptable and immunogenic therapeutic vaccination platforms. A spin-out company from the University of Helsinki, Finland, Valo Tx has assembled a talented team of immunotherapy experts, who together with the founding scientists have the necessary expertise to take its patented technology through clinical development and make it available to patients. The management team has a proven track record of developing successful companies from a laboratory idea to a full stock exchange listing.
Location: Finland, Mainland Finland, Helsinki
Employees: 11-50
Total raised: $22.98M
Founded date: 2016
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.03.2025 | - | $20.58M | - |
| 13.02.2023 | Grant | $2.4M | - |
Mentions in press and media 12
| Date | Title | Description |
| 12.03.2025 | Valo Therapeutics Secures €19 Million to Propel Cancer Immunotherapy Forward | In the realm of cancer treatment, innovation is the lifeblood. Valo Therapeutics Oy, a Finnish company, has just secured a significant boost—€19 million in funding. This financial windfall is not just a number; it represents hope, ambition,... |
| 10.03.2025 | Valo Therapeutics Receives EUR 19M in Funding | Valo Therapeutics Oy, a Helsinki, Finland-based cancer immunotherapy company, received EUR 19M in funding. The round consisted of €13M co-led by Indaco Venture Partners and CDP Venture Capital SGR with participation from Fondazione ENEA Tec... |
| 10.03.2025 | Valo Therapeutics announces EUR 19m of investment funding and expanded clinical trials | HELSINKI and NAPLES, Italy and PERTH, Australia, March 10, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy announces that it has successfully secured a financing round of €19 million, part of which was raised in Europe and part in Australia, ... |
| 14.02.2023 | Valo Therapeutics Raises EUR 2.23M from the European Innovation Council | Valo Therapeutics, a Helsinki, Finland-based developer of adaptable immunotherapies for cancer and infectious diseases, raised €2.23M from the European Innovation Council. The company intends to use the funds for a project to progress its i... |
| 15.11.2021 | Valo Therapeutics Raises €11M in Funding | Valo Therapeutics Oy, a Helsinki, Finland-based developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, raised €11m (approx. USD 12.75m) in Pre-IPO funding. Backers included Freeman Road, and new investors ... |
| 15.11.2021 | Finnish biotech startup Valo Therapeutics raises €11M to support the preparation of its IPO in 2022 | Helsinki-based Valo Therapeutics, an immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, announced that it has raised €11M in an oversubscribed pre-IPO funding round. With this, the company ha... |
| 01.02.2021 | Startups see new promise in old insight about viruses to stop cancer | Photo: Main_sail, Getty Images Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent,... |
| 10.02.2020 | Valo Therapeutics Raises EUR1.1M in Funding | Valo Therapeutics Limited, an Oxford, UK and Helsinki, Finland-based immuno-oncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines, received EUR1.1m in additional funding. The funding, triggered by posit... |
| 21.06.2019 | Maze interim chief Charles Homcy passes baton to Jason Coloma; William Collier tapped as CEO of Arbutus | Jason Coloma Third Rock → Four months into Maze Therapeutics’ launch, Charles Homcy is passing the startup’s reins to another Third Rock colleague. Jason Coloma, the current COO, is leaving his role at the VC firm to become... |
| - | Startups see new promise in old insight about viruses to stop cancer | For decades, scientists have known that viruses can kill cancer cells. The challenge has been harnessing that power safely and effectively. Buoyed by advances in immunotherapy and drug discovery, a new wave of researchers and companies is p... |
Show more